Hovione completes its Phase 2 clinical trial of the first minocycline ophthalmic
Showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction
Oops! Your browser version is not supported by our website.
Please use these following browsers to view this page:
Showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction
Its lead single-use nasal dry powder device now available for commercial partnerships
Hovione, the specialist integrated CDMO, just announced an expansion of its nasal drug delivery capabilities with the addition of a family of innovative nasal powder delivery devices developed in partnership with IDC.
Chemical companies, breweries, and perfumeries take to making and donating a vital commodity in short supply
Hovione today announced the appointment of Dr. Jean-Luc Herbeaux as Hovione’s Chief Executive Officer, effective 1st April 2022
Hovione has once again solidified its position as a top employer.
This certification is a recognition of Hovione´s resolve to put people first, and a validation that the investment in HR excellence is delivering.
Executiva, 23 February 2026